Fig. 5From: Multi-country clinical practice patterns, including use of biomarkers, among physicians’ treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)Country-specific top 3 ‘most impactful new therapies for BCG-unresponsive NMIBC patients’, as ranked by physiciansBack to article page